Pulmonary arterial hypertension: An overview of current pharmacologic treatment

Connecticut Medicine

Volumn 72, Issue 9, 2008, Pages 531-534

  Reinhart, Kurt ^a   Salerno, Edward ^a,b   White, C Michael ^a,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Division of Pulmonary and Critical Care Medicine ^*

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT;

ARTICLE; CLASSIFICATION; HUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY;

EID: 54049111932     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Berkowitz DS, Coyne NG: Understanding primary pulmonary hypertension. Crit Care Nurs Q 2003; 26:28-34.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115:343-9.
3. Sibon O, Humbert M, Jaïs X: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-11.
4. McLaughlin W, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114:1417-31.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1991; 327:76-81.
6. Badesh DB, Abham SH, Ahearn GS, et al: Medical therapy for pulmonary arterial hypertension. Chest 2004; 126:35S-62S.
7. Mickelakis E, Tymchak W, Lien D, et al: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 2002; 105:2398-403.
8. Ghofrani HA. Voswinckel R, Reichenberger F, et al: Differences in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary srterial hypertension. J Am Coll Cardiol 2004;44:1488-1496.
9. Physicians' Desk Reference: 61st ed. Montavale, New Jersey: Thompson PDR; 2007:2560.
10. Strauss WL, Edelman JD: Prostanoid therapy for pulmonary arterial hypertension. Clin Chest Med 2007; 28:127-42.
11. Barst RJ, Lewis RJ, McGoon MD, et al: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-15.
12. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Eng J Med 1996; 334:296-301.
13. Physicians' Desk Reference: 61st ed. Montavale, New Jersey: Thompson PDR; 2007:545.
14. Channick RN, Simonneau G, Sitbon O, et al: Effectsof the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study. Lancet 2001; 358:1119-23.
15. McLaughlin W: Survival in patients with pulmonary arterial nypertension treated with first-line bosentan. Eur J Clin Investigation 2006; 36:10-15.
16. Galie N, Badesch D, Oudiz R, et al: Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol.
17. Reinhart K, White CM: Focus on Sitaxsentan: A new agent for the treatment of pulmonary artery hypertension. Formulary 2007; 42:269-344.
18. Johnson SR, Mehta S, Granton JT: Anticoagulation in pulmonary arterial hypertension: A qualitative systematic review. Eur Respir J 2006; 28:999-1004.
19. Wilkens H, Guth A, König J, et al: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104:1218-22.
20. Ghofrani HA, Wiedemann R, Rose F. et al: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension, Ann Intern Med 2002; 136:515-22.
21. Mathai SC. Girgis RE, Fisher MR, et al: Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29:469-75.
22. Humbert M, Barst RJ, Robbins IM, et al: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353-9.